Background: Premature ejaculation (PE) is one of the sexual dysfunctions commonly present among patients with diabetes mellitus (DM), but rarely reported and not commonly investigated compared to erectile dysfunction....Background: Premature ejaculation (PE) is one of the sexual dysfunctions commonly present among patients with diabetes mellitus (DM), but rarely reported and not commonly investigated compared to erectile dysfunction. In this study, we aimed to investigate the prevalence of PE in a group of patients with type 2 DM and explore possible determinants of its occurrence and its association with erectile dysfunction. Methods: This was a cross-sectional study of subjects recruited from the Diabetes clinic and whose sexual function was assessed using the premature ejaculation diagnostic tool (PEDT) and erection hardness score (EHS), who were in heterosexuals relationship and resides together with their wives and had no major organ failure or acute infection within the last 1 month. Other socio-demographic history and diabetes-related questions were assessed. Results: A total of 69 subjects were recruited. The prevalence of PE was 27.5% in the study. There was a significant inverse relationship between the prevalence of premature ejaculation and frequency of sexual intercourse. Almost half 14/30 (46.7%) of those with erectile dysfunction had premature ejaculation. Diabetic patients with erectile dysfunction (ED) showed a significantly higher incidence of PE with significantly lower values of EHS. Higher level of fasting blood glucose was associated with higher prevalence of erectile dysfunction. Conclusions: The prevalence of PE was relatively high at 19/69 (27.5%) among our type 2 diabetic patients. Hence, health care giver should always endeavour to ask about it even when patients do not volunteer the information.展开更多
Premature ejaculation （PE） is the most common sexual disorder. It affects 20%-30% of adult men; the aetiology of this condition has not yet been elucidated. The aim of this study is to evaluate the efficacy, safety,...Premature ejaculation （PE） is the most common sexual disorder. It affects 20%-30% of adult men; the aetiology of this condition has not yet been elucidated. The aim of this study is to evaluate the efficacy, safety, tolerability, undesirable effects and improved satisfaction with sexual intercourse with tramadol hydrochloride at different dosages for the treatment of PE. A total of 300 patients who presented with lifelong （primary） PE were included in this study. The study was performed for 28 weeks, in which placebo （starch tablet） was given for 4 weeks, and active ingredient （tramadol hydrochloride） was administered at different therapeutic dosages for 24 weeks. Patients were divided into three equal groups, each consisting of 100 patients. The first group （A） was given tramadol hydrochloride capsule 25 mg. The second group （B） was given tramadol hydrochloride capsule 50 mg. The third group （C） was given tramadol hydrochloride capsule 100 mg. All of the 300 participants included completed the study voluntarily. The age of the patients varied from 25 to 50 years. After the treatment period, the recorded data were collected for each group and analysed. The results showed a highly significant increase in the mean intravaginal ejaculatory latency time （IELT） in all groups compared to baseline data （P〈0.0001）. We concluded that using tramadol hydrochloride at different doses on demand for the treatment of PE is effective, safe and tolerable, with minimal undesirable effects, and approval for this indication should be souRht.展开更多
文摘Background: Premature ejaculation (PE) is one of the sexual dysfunctions commonly present among patients with diabetes mellitus (DM), but rarely reported and not commonly investigated compared to erectile dysfunction. In this study, we aimed to investigate the prevalence of PE in a group of patients with type 2 DM and explore possible determinants of its occurrence and its association with erectile dysfunction. Methods: This was a cross-sectional study of subjects recruited from the Diabetes clinic and whose sexual function was assessed using the premature ejaculation diagnostic tool (PEDT) and erection hardness score (EHS), who were in heterosexuals relationship and resides together with their wives and had no major organ failure or acute infection within the last 1 month. Other socio-demographic history and diabetes-related questions were assessed. Results: A total of 69 subjects were recruited. The prevalence of PE was 27.5% in the study. There was a significant inverse relationship between the prevalence of premature ejaculation and frequency of sexual intercourse. Almost half 14/30 (46.7%) of those with erectile dysfunction had premature ejaculation. Diabetic patients with erectile dysfunction (ED) showed a significantly higher incidence of PE with significantly lower values of EHS. Higher level of fasting blood glucose was associated with higher prevalence of erectile dysfunction. Conclusions: The prevalence of PE was relatively high at 19/69 (27.5%) among our type 2 diabetic patients. Hence, health care giver should always endeavour to ask about it even when patients do not volunteer the information.
文摘Premature ejaculation （PE） is the most common sexual disorder. It affects 20%-30% of adult men; the aetiology of this condition has not yet been elucidated. The aim of this study is to evaluate the efficacy, safety, tolerability, undesirable effects and improved satisfaction with sexual intercourse with tramadol hydrochloride at different dosages for the treatment of PE. A total of 300 patients who presented with lifelong （primary） PE were included in this study. The study was performed for 28 weeks, in which placebo （starch tablet） was given for 4 weeks, and active ingredient （tramadol hydrochloride） was administered at different therapeutic dosages for 24 weeks. Patients were divided into three equal groups, each consisting of 100 patients. The first group （A） was given tramadol hydrochloride capsule 25 mg. The second group （B） was given tramadol hydrochloride capsule 50 mg. The third group （C） was given tramadol hydrochloride capsule 100 mg. All of the 300 participants included completed the study voluntarily. The age of the patients varied from 25 to 50 years. After the treatment period, the recorded data were collected for each group and analysed. The results showed a highly significant increase in the mean intravaginal ejaculatory latency time （IELT） in all groups compared to baseline data （P〈0.0001）. We concluded that using tramadol hydrochloride at different doses on demand for the treatment of PE is effective, safe and tolerable, with minimal undesirable effects, and approval for this indication should be souRht.
